Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions

Core Insights - The partnership between the Ladies Professional Golf Association (LPGA) and Ardelyx aims to educate and mobilize patients regarding digestive health, particularly focusing on women suffering from irritable bowel syndrome with constipation (IBS-C) [1][2] Group 1: Partnership Overview - Ardelyx has been named the official corporate pharmaceutical Marketing Partner of the LPGA Tour, marking a first-of-its-kind collaboration [1] - The partnership seeks to empower women to take control of their health and engage in open conversations about digestive health [2] Group 2: Health Focus - Women represent over 90% of individuals living with IBS-C, yet many face stigma and lack awareness, leading to isolation [2] - The collaboration aims to redefine discussions around IBS-C, emphasizing the importance of mental health, relationships, and work productivity affected by the condition [2] Group 3: Engagement Strategies - Ardelyx will implement a 360-degree approach to engage with the LPGA audience, including onsite experiences, storytelling, hospitality, and digital engagement [3] - The partnership will utilize LPGA platforms to distribute original digital and social content aimed at educating and connecting patients [2][3] Group 4: Organizational Background - The LPGA, established in 1950, is the premier women's professional golf organization, representing nearly 40 countries and providing opportunities for female golfers [4] - Ardelyx focuses on developing innovative medicines to address significant unmet medical needs, with two commercial products approved in the U.S. [6][7]